Free Trial

IM Cannabis (IMCC) Competitors

IM Cannabis logo
$2.90 +0.27 (+10.04%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$2.88 -0.03 (-1.03%)
As of 07/3/2025 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMCC vs. CVKD, CALC, OVID, GBIO, CMMB, ELEV, FGEN, DARE, FNCH, and RLMD

Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Cadrenal Therapeutics (CVKD), CalciMedica (CALC), Ovid Therapeutics (OVID), Generation Bio (GBIO), Chemomab Therapeutics (CMMB), Elevation Oncology (ELEV), FibroGen (FGEN), Dare Bioscience (DARE), Finch Therapeutics Group (FNCH), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.

IM Cannabis vs. Its Competitors

Cadrenal Therapeutics (NASDAQ:CVKD) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Cadrenal Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -9.10%. IM Cannabis' return on equity of -122.96% beat Cadrenal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cadrenal TherapeuticsN/A -244.94% -181.94%
IM Cannabis -9.10%-122.96%-11.69%

IM Cannabis has higher revenue and earnings than Cadrenal Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cadrenal TherapeuticsN/AN/A-$10.65M-$9.26-1.33
IM Cannabis$39.44M0.30-$7.72M-$0.64-4.54

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 48.6% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, IM Cannabis had 1 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 1 mentions for IM Cannabis and 0 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score.

Company Overall Sentiment
Cadrenal Therapeutics Neutral
IM Cannabis Neutral

Cadrenal Therapeutics currently has a consensus target price of $32.00, suggesting a potential upside of 160.37%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cadrenal Therapeutics is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cadrenal Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
IM Cannabis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cadrenal Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.

Summary

Cadrenal Therapeutics and IM Cannabis tied by winning 7 of the 14 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMCC vs. The Competition

MetricIM CannabisMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$11.74M$10.41B$5.53B$9.02B
Dividend YieldN/A2.07%5.22%3.99%
P/E Ratio-4.5417.0327.7020.25
Price / Sales0.3029.81419.56119.26
Price / CashN/A23.9726.2128.59
Price / Book2.823.668.035.65
Net Income-$7.72M$235.43M$3.18B$249.15M
7 Day Performance17.14%1.53%2.88%2.91%
1 Month Performance5.25%1.07%1.67%4.11%
1 Year Performance15.55%-10.17%34.39%20.98%

IM Cannabis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMCC
IM Cannabis
0.3314 of 5 stars
$2.91
+10.0%
N/A+15.6%$11.74M$39.44M-4.54340
CVKD
Cadrenal Therapeutics
2.8386 of 5 stars
$11.59
-3.8%
$32.00
+176.1%
N/A$22.83MN/A-1.254Positive News
Gap Up
CALC
CalciMedica
3.0724 of 5 stars
$1.63
+1.9%
$18.00
+1,004.3%
-61.8%$22.77MN/A-1.0430Gap Up
OVID
Ovid Therapeutics
4.222 of 5 stars
$0.32
-3.3%
$3.13
+879.6%
-53.9%$22.76M$570K-0.9160High Trading Volume
GBIO
Generation Bio
2.9469 of 5 stars
$0.33
+4.0%
$7.33
+2,102.2%
-83.9%$22.32M$19.89M-0.31150
CMMB
Chemomab Therapeutics
2.8878 of 5 stars
$1.18
+1.7%
$8.50
+620.3%
+19.8%$22.26MN/A-1.5520
ELEV
Elevation Oncology
1.9133 of 5 stars
$0.37
+0.2%
$3.39
+820.0%
-86.5%$21.79MN/A-0.4540
FGEN
FibroGen
4.7129 of 5 stars
$5.33
+0.6%
$250.00
+4,590.4%
-68.5%$21.53M$29.62M-2.13570Positive News
Gap Up
DARE
Dare Bioscience
1.5766 of 5 stars
$2.41
+0.6%
$12.00
+399.0%
-23.8%$21.28M$10K-14.1530News Coverage
FNCH
Finch Therapeutics Group
1.0554 of 5 stars
$13.20
flat
N/A+929.5%$21.20M$110K-1.50190
RLMD
Relmada Therapeutics
4.6142 of 5 stars
$0.63
+5.6%
$5.00
+688.6%
-79.2%$21.04MN/A-0.2510Gap Up

Related Companies and Tools


This page (NASDAQ:IMCC) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners